A phase 3 study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor risk

• T. Choueiri,
• L. Albiges,
• T. Powles,
• A. Geng,
• N. Mohamed,
• F. Wang,
• R.J. Motzer

Affiliations

T. Choueiri

L. Albiges

T. Powles

A. Geng

N. Mohamed

F. Wang

R.J. Motzer